Alzheimer's disease

After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Thu, 07/20/23 - 10:09 am
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
subcutaneous drug delivery
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
AAIC 2023 – Acumen’s new amyloid approach impresses
EP Vantage
Wed, 07/19/23 - 10:15 am
AAIC
Acumen
Alzheimer's disease
ACU193
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
Tue, 07/18/23 - 11:55 am
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
BioSpace
Tue, 07/18/23 - 11:36 am
CMS
Alzheimer's disease
Eisai
Biogen
PET scans
Lilly shares full pivotal data on Alzheimer’s drug, revealing how it shapes up against Leqembi
Fierce Biotech
Mon, 07/17/23 - 06:51 pm
Eli Lilly
Alzheimer's disease
clinical trials
FDA
donanemab
Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug
Clinical Trials Arena
Mon, 07/17/23 - 08:41 am
Alnylam
clinical trials
ALN-APP
Alzheimer's disease
Why new Alzheimer’s drugs are in for a tepid launch
Medical Marketing and Media
Sun, 07/16/23 - 03:11 pm
Alzheimer's disease
drug launches
Biogen
Eisai
Leqembi
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
Motley Fool
Thu, 07/13/23 - 10:16 am
Biogen
Eisai
Leqembi
Alzheimer's disease
How will the price of Eisai and Biogen's Leqembi impact Medicare? Sen. Sanders wants to know
Fierce Pharma
Wed, 07/12/23 - 11:03 pm
Eisai
Biogen
Leqembi
drug pricing
Medicare
Alzheimer's disease
Eisai's US CEO and Alzheimer's lead Ivan Cheung telegraphs retirement days after Leqembi's full FDA nod
Fierce Pharma
Tue, 07/11/23 - 11:20 pm
Eisai
Alzheimer's disease
Leqembi
Ivan Cheung
BMS makes quickfire bets on neurodegeneration, paying $95M to exercise Evotec, Prothena options
Fierce Biotech
Tue, 07/11/23 - 10:13 am
Bristol Myers Squibb
neurodegenerative disease
Prothena
Alzheimer's disease
Evotec
Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s
BioSpace
Thu, 07/6/23 - 10:08 pm
Biogen
Eisai
Leqembi
FDA
Alzheimer's disease
Why Shares of Cassava Sciences Are Dropping Wednesday
Motley Fool
Wed, 07/5/23 - 07:01 pm
Cassava Sciences
simufilam
Alzheimer's disease
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
BioXCell’s potential episodic Alzheimer’s agitation treatment marred by missed trial protocols, fabricated emails and failed endpoint
Fierce Pharma
Thu, 06/29/23 - 11:42 am
BioXCell
Alzheimer's disease
Alzheimer's agitation
dexmedetomidine
SEC
Brainwave: Cognition gets ideas about effect of Alzheimer's prospect from midphase data
Fierce Biotech
Wed, 06/28/23 - 10:00 am
Cognitition Therapeutics
Alzheimer's disease
clinical trials
CT1812
Medicare has no surprises in planned registry for new Alzheimer’s drugs
BioPharma Dive
Sun, 06/25/23 - 09:40 pm
Medicare
Alzheimer's disease
CMS
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
Motley Fool
Fri, 06/23/23 - 10:03 am
Biogen
Eisai
Alzheimer's disease
FDA
Leqembi
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Motley Fool
Mon, 06/19/23 - 10:21 am
Eisai
Biogen
Leqembi
Alzheimer's disease
Europe

Pages